Skip to main content

Table 1 Patient and treatment characteristics

From: Radiomics for prediction of radiation-induced lung injury and oncologic outcome after robotic stereotactic body radiotherapy of lung cancer: results from two independent institutions

  Training set   Test set  
  (n = 110)   (n = 71)  
Age (median/range) 73y (50–94 year)   75y (48–88 year)  
Gender (male/female) 58/52 (53%/47%)   47/24 (66%/34%)  
Tumor diameter (median/range) 2.2 cm (0.8–6.6 cm)*   2.6 cm (1.1–6.0 cm)#  
Tumor stage (UICC8), T1/T2 89/21 (81%/19%)   45/26 (63%/37%)  
Pathological confirmation (Yes/No) 91/19 (83%/17%)   55/16 (77%/23%)  
Mediastinal staging     
 CT only 18 (16%)   5 (7%)  
 CT + PET 52 (47%)   33 (47%)  
 CT + EBUS 18 (16%)   16 (23%)  
 CT + EBUS + PET 18 (16%)   17 (24%)  
 CT + mediastinoscopy 3 (3%)   
 CT + PET + mediastinoscopy 1 (1%)   
Histology     
 Adenocarcinoma 37 (34%)   23 (32%)  
 Squamous cell 42 (38%)   28 (39%)  
 Other 12 (11%)   4 ( 6%)  
 Unknown 19 (17%)   16 (23%)  
Fractionation scheme     
Number of fractions Dose per fraction n Pat Dose per fraction n Pat
 1 25 Gy 5 (5%) 26–27 Gy 2 (3%)
 3 17 Gy 45 (41%) 13–18 Gy 65 (90%)§
 5 11 Gy 43 (39%) 10–11 Gy 3 (6%)
 8 7.5 Gy 17 (16%) 6.0 Gy 1 (1%)
Doses to GTV, PTV and lung (median/ range)     
 GTV Dmax 84.6 (28.2–95.2) Gy   70.9 (41.5–84.6) Gy  
 GTV Dmean 71.6 (26.2–84.0) Gy   62.7 (37.9–72.5) Gy  
 GTV D95% 61.9 (21.8–75.9) Gy   53.8 (33.0–64.6) Gy  
 PTV D95% 54.0 (19.0–67.1) Gy   45.3 (25.2–55.2) Gy  
 Lung D1ml 65.6 (23.6–81.0) Gy   55.5 (37.7–71.6) Gy  
 Lung D10ml 52.1 (15.8–78.9) Gy   47.5 (25.8–66.9) Gy  
 Lung D50ml 31.3 (6.9–77.7) Gy   31.6 (11.2–51.9) Gy  
 Lung D100ml 20.5 (4.5–77.0) Gy   20.5 (6.6–43.0) Gy  
GTV-PTV margin 3–4 mm   3–5 mm  
Tracking Mode (Fiducials/XSightLung) 15/95 (14%/86%)   6/65 (9%/91%)  
  1. *1 pt. > 5 cm
  2. #3 pts. > 5 cm
  3. §1 pt. 4 × 10 Gy